The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma., PMID:40509933
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers., PMID:40507303
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data., PMID:40507234
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies., PMID:40481574
Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer., PMID:40458070
Adverse cardiac events associated with antibody drug conjugates in cancer patients: a retrospective analysis on the FAERS database and randomized controlled trials., PMID:40455883
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial., PMID:40450142
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer., PMID:40440007
Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899
Last Resort? Rationale for Comprehensive Molecular Analysis in Treatment-Refractory R/M HNSCC: A Case Report of Remarkable Response to Sacituzumab Govitecan Following Molecular and Functional Characterization., PMID:40427091
Assessment of trophoblast cell-surface antigen 2 (TROP2) and nectin-4 expression in choriocarcinoma., PMID:40414312
Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies., PMID:40403357
Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4., PMID:40380880
LBA and LC-MS/MS based comprehensive bioanalytical methods for FDA018, a Trop-2 targeted antibody-drug conjugate., PMID:40375398
[Translated article] Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative review., PMID:40368667
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan., PMID:40366333
The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey., PMID:40361516
Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option☆., PMID:40359710
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156
TROP2 expression and therapeutic targeting in uterine carcinosarcoma., PMID:40344963
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
Datopotamab Deruxtecan: First Approval., PMID:40323341
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma., PMID:40299780
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer., PMID:40297626
Pretargeting: Bridging the two worlds of radiopharmaceutical probes., PMID:40293376
Therapeutic Potential of Datopotamab Deruxtecan in the Treatment of Advanced Non-Small Cell Lung Cancer: Evidence to Date., PMID:40291609
[Diffuse interstitial lung disease induced by antibody-drug conjugates]., PMID:40263022
Modular assembly and evaluation of a TROP2-targeting immunotoxin for cancer therapy., PMID:40253026
Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer., PMID:40252843
Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution., PMID:40238068
Epitope Expression Persists in Circulating Tumor Cells as Breast Cancers Acquire Resistance to Antibody Drug Conjugates., PMID:40235972
Trop-2 expression in non-small cell lung cancer., PMID:40233061
FDA approves Datroway: a novel therapy for HR-positive, HER2-negative metastatic breast cancer., PMID:40212175
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials., PMID:40210967
Trop2-expression in primary vulvar squamous cell carcinoma., PMID:40184712
Safety and Tolerability of Concurrent Radiotherapy and Sacituzumab Govitecan in Metastatic Breast Cancer., PMID:40178882
Targeting the tumour cell surface in advanced prostate cancer., PMID:40169837
Advances in adoptive cell therapies in small cell lung cancer., PMID:40160238
Recent advances in therapeutic strategies for non-small cell lung cancer., PMID:40140911
Influence of the UGT1A1 gene polymorphism on treatment with sacituzumab govitecan. Narrative review., PMID:40140308
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics., PMID:40139025
Identification of Tumor-Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma., PMID:40130819
Advances in antibody-drug conjugates for endometrial cancer., PMID:40111079
[Preparation of Trop2-Targeted CAR-T Cells Based on Nanobodies and Their Antitumor Effects Against Non-Small Cell Lung Cancer]., PMID:40109477
Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road., PMID:40104722
Spatial Expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management., PMID:40086591
Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy., PMID:40082588
Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review., PMID:40072062
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan., PMID:40064573
For research use only. Not for human or drug use.
